Unicycive Therapeutics appoints Meredith Manning to board, names her nominating committee chair
UNCY•Unicycive Therapeutics appointed Meredith Manning to its board and named her chair of the nominating and corporate governance committee. Manning also joined the audit and compensation committees.
1. Board appointment
Unicycive Therapeutics appointed Meredith Manning to its board. She joined the audit, compensation, nominating and corporate governance committees and will chair the nominating and corporate governance committee.
2. Prior role
Manning was chief commercial officer at Soleno Therapeutics from 2024 until its 2026 acquisition by Neurocrine Biosciences.
